SECRETIN Drug Patent Profile
✉ Email this page to a colleague
When do Secretin patents expire, and when can generic versions of Secretin launch?
Secretin is a drug marketed by Ferring and is included in one NDA.
The generic ingredient in SECRETIN is secretin. There are six drug master file entries for this compound. Additional details are available on the secretin profile page.
Summary for SECRETIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SECRETIN at DailyMed |
Recent Clinical Trials for SECRETIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Hospital Medical Center, Cincinnati | Phase 4 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 4 |
Steno Diabetes Center Copenhagen | N/A |
Medical Subject Heading (MeSH) Categories for SECRETIN
US Patents and Regulatory Information for SECRETIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ferring | SECRETIN-FERRING | secretin | INJECTABLE;INJECTION | 018290-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |